Antonio D’Alessio, Honorary Senior Lecturer at The Roger Williams Institute of Liver Studies, shared on LinkedIn:
“Fresh off the press – the PRIME-HCC trial on the Lancet Oncology.
- We conducted the first European neoadjuvant trial, demonstrating that:
2 cycles of nivo-ipi prior to resection did not increase the risk of treatment-related surgical delays, with 9% G3 trAE and no G4-5 - A short course of neoadjuvant ICI achieved an ORR 25% (41% with mRECIST) and an MPR90 of 30%
- The risk of primary progression during neoadjuvant ICI was negligible, with a DCR of 97%
- ctDNA (assessed with a 20-gene panel) predicted response to neoadjuvant ICI and detected post-resection MRD with higher risk of recurrence
- Response to ICI and long-term survival was associated with specific T cell subpopulations in the TME and in the periphery (in particular Tpex) and TCRbeta clonality
Our results are brilliantly contextualised in the Comment by Eric Assenat
A massive thanks to David James Pinato for his vision, believing in the role of neoadjuvant ICI already 10 years ago to the Freiburg lab and to all the other collaborators at Imperial and beyond: now time to move to the next trial!”
Title: Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses
Authors: Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Madhava Pai, Alexandra Emilia Schlaak, Duncan Spalding, Ira Godbole, Robert D. Goldin, Nicole Acuti, Caroline Ward, Georgios Nteliopoulos, Vincent Yip, Sarah Slater, Poyyamozhi Rajagopal, Mikael Sodergren, Paul Tait, Nagy Habib, Robert Thomas, Eslam Maher, Francesco A. Mauri, Alessio Cortellini, Julian R. Marchesi, Bertram Bengsch, Rohini Sharma, David James Pinato
Read the full article:
You may also be interested in:
PRIME-HCC Trial: Neoadjuvant Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma
